Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia.
Alzheimer's disease
amyloid
atrophy
magnetic resonance imaging
solanezumab
volumetric magnetic resonance imaging
Journal
Alzheimer's & dementia (New York, N. Y.)
ISSN: 2352-8737
Titre abrégé: Alzheimers Dement (N Y)
Pays: United States
ID NLM: 101650118
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
09
2021
revised:
23
03
2022
accepted:
05
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Solanezumab is a monoclonal antibody that preferentially binds soluble amyloid beta and promotes its clearance from the brain. The aim of this post hoc analysis was to assess the effect of low-dose solanezumab (400 mg) on global brain volume measures in patients with mild or moderate Alzheimer's disease (AD) dementia quantified using volumetric magnetic resonance imaging (vMRI) data from the EXPEDITION clinical trial program. Patients with mild or moderate AD (EXPEDITION and EXPEDITION2) and mild AD (EXPEDITION3), were treated with either placebo or solanezumab (400 mg) every 4 weeks (Q4W) for 76 weeks. vMRI scans were acquired at baseline and at 80 weeks from 427 MRI facilities using a standardized imaging protocol. Whole brain volume (WBV) and ventricle volume (VV) changes were estimated at 80 weeks using either boundary shift integral (EXPEDITION and EXPEDITION2) or tensor-based morphometry (EXPEDITION3). The pooled cohort used for this study consisted of participants with vMRI at baseline and week 80 across the three trials. Analyzed patient subgroups comprised full patient cohort ( Analysis of patients with mild or moderate AD dementia from baseline to 80 weeks using vMRI measures of WBV and VV changes suggested that low-dose solanezumab was not linked to changes in volumes at 80 weeks. Analysis of the pooled cohort did not demonstrate an effect on brain volumes with treatment. Evaluation of a higher dose of solanezumab in the preclinical stage of AD is currently being undertaken.
Identifiants
pubmed: 35783453
doi: 10.1002/trc2.12313
pii: TRC212313
pmc: PMC9237342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12313Informations de copyright
© 2022 Eli Lilly and Company. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Déclaration de conflit d'intérêts
Diana O. Svaldi, Ixavier A. Higgins, Karen C. Holdridge, Roy Yaari, Michael Case, Sergey Shcherbinin, and John R. Sims are all employees and minor shareholders of Eli Lilly and Company. Diana O. Svaldi has received support from Eli Lilly and Company for attending meetings and/or travel. Luc Bracoud and David Scott have nothing to report.
Références
Neurology. 2005 May 10;64(9):1563-72
pubmed: 15883317
Neuroimage. 2008 Nov 15;43(3):458-69
pubmed: 18691658
N Engl J Med. 2021 May 6;384(18):1691-1704
pubmed: 33720637
J Alzheimers Dis. 2015;49(4):1123-34
pubmed: 26639957
Alzheimers Dement. 2016 Feb;12(2):110-120
pubmed: 26238576
Med Image Comput Comput Assist Interv. 2008;11(Pt 1):754-61
pubmed: 18979814
N Engl J Med. 2018 Jan 25;378(4):321-330
pubmed: 29365294
N Engl J Med. 2014 Jan 23;370(4):311-21
pubmed: 24450890
Alzheimers Res Ther. 2017 Dec 8;9(1):95
pubmed: 29221491
Cell. 2019 Oct 3;179(2):312-339
pubmed: 31564456
Brain. 2020 Dec 1;143(12):3816-3826
pubmed: 33253354
JAMA Neurol. 2020 Jun 1;77(6):735-745
pubmed: 32250387
Alzheimers Dement (N Y). 2019 Jul 30;5:328-337
pubmed: 31388559
J Magn Reson Imaging. 1997 Nov-Dec;7(6):1069-75
pubmed: 9400851
Nat Rev Neurol. 2010 Feb;6(2):67-77
pubmed: 20139996
Science. 2002 Mar 22;295(5563):2264-7
pubmed: 11910111
Alzheimers Res Ther. 2016 May 12;8(1):18
pubmed: 27176461
Dement Geriatr Cogn Disord. 2020;49(4):334-348
pubmed: 33321511
JAMA Neurol. 2015 Nov;72(11):1324-33
pubmed: 26414022
Ageing Res Rev. 2021 Jul;68:101339
pubmed: 33831607
Contemp Clin Trials. 2021 Jul;106:106421
pubmed: 33940253
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12123
pubmed: 33614894
Alzheimers Res Ther. 2021 Apr 17;13(1):80
pubmed: 33865446
J Prev Alzheimers Dis. 2022;9(2):197-210
pubmed: 35542991
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Med Image Anal. 2008 Feb;12(1):26-41
pubmed: 17659998
Magn Reson Imaging. 2000 May;18(4):439-53
pubmed: 10788722